• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Nordisk touts Tresiba insulin injection data

November 30, 2016 By Sarah Faulkner

Nordisk touts Tresiba insulin injection dataNovo Nordisk (NYSE:NVO) said today that data from the Devote clinical trial indicated that its injected insulin, Tresiba, reduced the risk of severe hypoglycemia when compared to insulin glargine.

The trial enrolled more than 7,500 type 2 diabetes patients at high risk of adverse cardiovascular events and treated them for 2 years with either Tresiba or insulin glargine U100. The long term analysis sought to confirm interim data that the Denmark-based company used to support its FDA approval for Tresiba in September last year.

The Devote trial met its primary endpoint, demonstrating non-inferiority of major adverse cardiovascular events with the injected insulin degludec compared to insulin glargine. There was no statistical difference between the 2 treatments and their safety profiles, the company reported.

From a mean HbA1c baseline of 8.4%, Tresiba demonstrated a similar reduction in blood sugar compared to insulin glargine U100. The basal insulin injection met its secondary endpoint, in which 27% fewer patients in the Tresiba arm experienced severe hypoglycemia. Patients in the Tresiba group also experienced a 54% relative reduction in the rate of nocturnal severe hypoglycemia.

“We are very pleased that the Devote study demonstrates the cardiovascular safety of Tresiba and also confirms the hypoglycaemia benefit of this new generation insulin. Severe hypoglycaemia remains the most serious treatment risk related to insulin therapy,” executive VP & chief science officer Mads Krogsgaard Thomsen said in prepared remarks. “The Devote results further strengthen the potential of Tresiba to become the new standard of care within basal insulin therapy.”

NVO shares were trading at $33.55 in mid-afternoon activity, up +2.5%.

Filed Under: Clinical Trials, Diabetes, Featured, Food & Drug Administration (FDA), Pharmaceuticals Tagged With: Novo Nordisk

IN CASE YOU MISSED IT

  • Dexcom updates CGM receiver recall that led to serious adverse events
  • Abbott reports momentum with Libre CGM business as new dual sensor will ‘accelerate’ growth
  • Johnson & Johnson wins FDA priority review for drug delivery system
  • Glucose monitoring company LifeScan files chapter 11 to reduce debt
  • Medtronic enrolls first patient in study for Onyx liquid embolic system

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS